Conor tests dual-drug-eluting coronary stent:
This article was originally published in Clinica
Conor Medsystems has performed the first patient implant of its dual-drug-eluting coronary stent for preventing restenosis, as a lead-in case to the start of its GENESIS clinical trial. The 375-patient study, which is scheduled to start enrolling patients this summer, is assessing the firm's pimecrolimus/paclitaxel-eluting stent, SymBio. It will also test Conor's investigational pimecrolimus-eluting stent, Corio, and will compare both new devices with the firm's CoStar cobalt chromium paclitaxel-eluting stent, which is already CE-marked for sale in Europe. The SymBio stent capitalises on the advantages of Conor's reservoir-based stent design to deliver more than one drug, said the Menlo Park, California firm. The GENESIS trial is expected to complete patient-enrolment in late 2006 or early 2007.